Stressgen's European patent upheld against challenge from Antigenics

By Angela McDaniels

Seattle, Oct. 19 - Stressgen Biotechnologies said an Opposition Division of the European Patent Office has granted judgment in favor of Stressgen on a patent challenge from Antigenics. The patent is now in force until 2018.

Antigenics may appeal the decision.

Antigenics filed an opposition to Stressgen's patent in 2003 and cited over 140 documents to support its arguments, said Stressgen.

The patent covers fusion proteins made of a heat shock protein and a human papillomavirus (HPV) protein antigen that are capable of inducing or enhancing a cell-mediated, cytolytic immune response in patients.

The claims also cover related products, such as nucleic acids encoding the fusion protein and pharmaceutical compositions containing the fusion protein.

Stressgen, a biopharmaceutical company based in Victoria, B.C., develops stress protein-based immunotherapeutics, also known as therapeutic vaccines, used in the treatment of infectious diseases and cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.